Cited 8 times in
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노미령 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 이충근 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 허수진 | - |
dc.date.accessioned | 2016-02-04T12:03:42Z | - |
dc.date.available | 2016-02-04T12:03:42Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141804 | - |
dc.description.abstract | PURPOSE: There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. MATERIALS AND METHODS: We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m(2) on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days. Primary end point was objective response rate (ORR). RESULTS: Thirty patients were enrolled in the study, and the median follow-up duration was 19.8 months. Among 25 per-protocol patients, there were three responders (1 with complete response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among the per-protocol population, the median progression-free survival (PFS) was 4.3 months and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9) showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9 months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%). CONCLUSION: Docetaxel combined with carboplatin showed association with an acceptable safety profile and overall efficacy for patients with malignant melanoma who had progressed on chemotherapy containing dacarbazine. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 781~789 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject.MESH | Carboplatin/administration & dosage | - |
dc.subject.MESH | Carboplatin/adverse effects | - |
dc.subject.MESH | Carboplatin/therapeutic use* | - |
dc.subject.MESH | Dacarbazine/administration & dosage | - |
dc.subject.MESH | Dacarbazine/adverse effects | - |
dc.subject.MESH | Dacarbazine/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Melanoma/drug therapy* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Patient Compliance | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Taxoids/adverse effects | - |
dc.subject.MESH | Taxoids/therapeutic use* | - |
dc.subject.MESH | Young Adult | - |
dc.title | Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Dermatology (피부과학) | - |
dc.contributor.googleauthor | Choong-kun Lee | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Su Jin Heo | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.contributor.googleauthor | Mi Ryung Roh | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.identifier.doi | 10.4143/crt.2014.261 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01278 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A03259 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A04355 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 25687848 | - |
dc.subject.keyword | Carboplatin | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | Melanoma | - |
dc.subject.keyword | Second-line chemotherapy | - |
dc.contributor.alternativeName | Roh, Mi Ryung | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Lee, Choong Kun | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Heo, Su Jin | - |
dc.contributor.affiliatedAuthor | Roh, Mi Ryung | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Lee, Choong Kun | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Heo, Su Jin | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 47 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 781 | - |
dc.citation.endPage | 789 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.47(4) : 781-789, 2015 | - |
dc.identifier.rimsid | 30901 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.